Information Links
Mims
Main Navigation
Drugs
Conditions
ArticlesGuidelines - Endocrine
Quick-reference summaries of key national treatment guidance for endocrine disorders including osteoporosis and growth hormone deficiency.
NICE technology appraisals
Decisions by the National Institute for Health and Care Excellence on NHS access to treatments for endocrine disorders.
-
Denosumab for the Treatment of Therapy-Induced Bone Loss in Non-Metastatic Prostate Cancer (terminated appraisal) (TA194)
-
Denosumab for the Prevention of Skeletal-Related Events in Adults with Bone Metastases from Solid Tumours (TA265)
-
Denosumab for the Prevention of Osteoporotic Fractures in Postmenopausal Women (TA204)
-
Growth Failure in Children: Human Growth Hormone (Somatropin) (NICE)
-
Growth Hormone Deficiency in Adults: Human Growth Hormone (Somatropin) (NICE)
MIMS Clinics
Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.
